Username:
Password:
Forgot your password
|
Become a member
About GOC
Meetings and Events
CME
Case Presentations
News
Membership
Patient Advocacy
Resources
GOC Position Statement - Intraperitoneal Chemotherapy for Ovarian Cancer
GOC Position Statement - Prophylactic HPV Vaccines
GOC Position on NACI Statement on Human Papillomavirus Vaccine
GOC Position Statement Regarding Ovarian Cancer Screening
GOC Statement regarding CA125 Monitoring in the Management of Recurrent Ovarian Cancer
GOC Position Statement Regarding the Resignation of Three Gynecologic Oncologists in Newfoundland and Labrador
GOC Position Statement of Cervical Cancer Vaccines
GOC Statement regarding CA125 Monitoring in the Management of Recurrent Ovarian Cancer
June 12, 2009
GOC Statement regarding CA125 Monitoring in the Management of Recurrent Ovarian Cancer (June 2009, PDF)
Communiqué de la Société de gynéco-oncologie du Canada - Utilité du CA125 dans le suivi des cancers de l’ovaire (juin 2009, version française, PDF)
A founding partner of CG²
